Merck
MRK
#53
Rank
โ‚ฌ254.07 B
Marketcap
102,87ย โ‚ฌ
Share price
-1.42%
Change (1 day)
46.75%
Change (1 year)

P/E ratio for Merck (MRK)

P/E ratio as of June 2026 (TTM): 33.7

According to Merck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.6796. At the end of 2025 the company had a P/E ratio of 14.4.

P/E ratio history for Merck from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202514.4-0.02%
202414.4-97.87%
20236793674.95%
202218.034.71%
202113.4-44.9%
202024.227.46%
201919.0-25.19%
201825.4-44.27%
201745.6116.87%
201621.0-11.64%
201523.8152.83%
20149.42-58.32%
201322.686.02%
201212.16.11%
201111.4

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
27.5-18.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
21.9-35.11%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
20.0-40.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
24.3-27.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
40.5 20.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
24.4-27.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
17.3-48.65%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
16.0-52.36%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
13.7-59.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
25.0-25.84%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.